Reuters: Health News 2 April 2018

FDA refuses to review Alkermes' depression treatment, seeks more trials

(Reuters) - Alkermes Plc has been told to conduct more clinical trials of its experimental depression treatment after the U.S. Food and Drug Administration rejected its initial application for approval, citing a lack of evidence of its effectiveness.

Read More →